SYDNEY, April 17 (Reuters) - China's Giant Biogene has raised about $301 million in a Hong Kong top up placement, according to a term sheet seen by Reuters.
The company sold 35 million shares at HK$66.65, a 9.5% discount to Giant Biogene's closing price on the Hong Kong Stock Exchange on Wednesday, the term sheet showed. The final price was at the bottom end of the price range flagged to investors when the deal launched.
(Reporting by Scott Murdoch; Editing by Leslie Adler)
((Scott.Murdoch@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.